Sandoz' AirFluSal Forspiro inhaler better than Advair/Seretide Diskus, data suggest

31 August 2016
drugs_pills_tablets_big

New data shows that the rate of treatment persistence for patients using the AirFluSal Forspiro respiratory inhaler, developed by Swiss pharma giant Novartis’ (NOVN: VX) generics and biosimilar division Sandoz, is more than twice as high as for the reference product.

That reference product is Advair/Seretide Diskus (salmeterol/fluticasone propionate combination) from UK pharma major GlaxoSmithKline (LSE: GSK).

The analysis, published in the Journal of Allergy and Clinical Immunology: In Practice, is the largest European real-world evidence (RWE) study ever conducted in asthma and chronic obstructive pulmonary disease (COPD). It highlights the importance of improving treatment persistence over time for long-term respiratory diseases.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics